Literature DB >> 12920337

Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy.

Erdoğan Cicik1, Hasan Tekin, Solmaz Akar, Ozlem Balci Ekmekçi, Orkide Donma, Lale Koldaş, Sehirbay Ozkan.   

Abstract

PURPOSE: To evaluate interleukin-8 (IL-8), nitric oxide (NO) and glutathione (GSH) profiles in vitreous humor and blood samples in patients with proliferative diabetic retinopathy (PDR) and in patients with proliferative vitreoretinopathy (PVR) and to compare the levels with those of controls. PATIENTS AND METHODS: NO concentrations were determined by using the Greiss reaction in plasma and vitreous humor samples. GSH levels were determined in both blood and vitreous humor samples, using DTNB, a disulfide chromogen. Vitreous IL-8 were assayed by ELISA. Twenty-three patients with PDR, 18 patients with PVR and 21 cadavers as the control group were included in the study.
RESULTS: Plasma and vitreous NO levels were found to be 25.6 +/- 2.1 and 36.9 +/- 3.0 micromol/l in patients with PDR, 27.0 +/- 4.7 and 34.3 +/- 2.9 micromol/l in patients with PVR and 17.4 +/- 2.7 and 15.9 +/- 1.4 micromol/l in controls, respectively. Vitreous humor and plasma NO levels did not show any statistically significant difference between PDR and PVR groups. However, the values for vitreous in both groups were significantly higher than those of controls (p < 0.0001). Although IL-8 levels in vitreous samples of patients with PDR were not significantly different (79.6 +/- 9.7 pg/ml) from those of patients with PVR (42.2 +/- 7.3 pg/ml) (p = 0.06), the levels in both groups were significantly higher than those of controls (19.0 +/- 3.9 pg/ml) (p < 0.0001 and p < 0.05, respectively). Blood and vitreous GSH levels were found to be 5.3 +/- 0.4 micromol/g. Hb and 0.58 +/- 0.16 micromol/l in patients with PDR and 8.4 +/- 0.5 micromol/g. Hb and 15.7 +/- 2.2 micromol/l in patients with PVR and 12.0 +/- 1.1 micromol/g. Hb and 0.26 +/- 0.03 mmol/l in controls, respectively. Vitreous and blood GSH levels were significantly lower in patients with PDR compared to those with PVR (p < 0.0001 for both).
CONCLUSION: Elevated levels of vitreous and plasma NO and vitreous IL-8 in PDR and PVR implicate a role for these parameters in the proliferation in these ocular disorders. GSH concentrations both in vitreous and blood samples of the PVR and PDR patients were much less than those observed in the control group. Lower GSH concentrations detected in PDR in comparison with those in PVR in vitreous humor and to a lesser degree in blood may play an important role in pathogenesis of new retinal vessel formation in patients with PDR. This also suggests that oxidative stress may be involved in the pathogenesis of PVR and particularly that of PDR. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920337     DOI: 10.1159/000072145

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  16 in total

1.  Measurement of region-specific nitrate levels of the posterior chamber of the rat eye using low-flow push-pull perfusion.

Authors:  Jeanita S Pritchett; Jose S Pulido; Scott A Shippy
Journal:  Anal Chem       Date:  2008-06-13       Impact factor: 6.986

2.  Association of hypoglutathionemia with reduced Na+/K+ ATPase activity in type 2 diabetes and microangiopathy.

Authors:  Rangasamy Sampathkumar; Muthuswamy Balasubramanyam; Cherian Tara; Mohan Rema; Viswanathan Mohan
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Capillary electrophoretic assay for nitrate levels in the vitreous of proliferative diabetic retinopathy.

Authors:  Leyi Gao; Jose S Pulido; R Mark Hatfield; Robert F Dundervill; Colin A McCannel; Scott A Shippy
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-11-13       Impact factor: 3.205

Review 4.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

5.  Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body.

Authors:  Hiroshi Izuta; Nozomu Matsunaga; Masamitsu Shimazawa; Tetsuya Sugiyama; Tsunehiko Ikeda; Hideaki Hara
Journal:  Mol Vis       Date:  2010-01-29       Impact factor: 2.367

6.  The gel state of the vitreous and ascorbate-dependent oxygen consumption: relationship to the etiology of nuclear cataracts.

Authors:  Ying-Bo Shui; Nancy M Holekamp; Benjamin C Kramer; Jan R Crowley; Mark A Wilkins; Fred Chu; Paula E Malone; Shayna J Mangers; Joshua H Hou; Carla J Siegfried; David C Beebe
Journal:  Arch Ophthalmol       Date:  2009-04

7.  TOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors.

Authors:  B Cameron Carr; Caitlyn E Emigh; Lea D Bennett; Andrew D Pansick; David G Birch; Chan Nguyen
Journal:  Retina       Date:  2017-01       Impact factor: 4.256

8.  Levels of selected oxidative stress markers in the vitreous and serum of diabetic retinopathy patients.

Authors:  Vlatka Brzović-Šarić; Irena Landeka; Borna Šarić; Monika Barberić; Lidija Andrijašević; Branimir Cerovski; Nada Oršolić; Domagoj Đikić
Journal:  Mol Vis       Date:  2015-06-12       Impact factor: 2.367

Review 9.  The role of microglia in diabetic retinopathy.

Authors:  Jeffery G Grigsby; Sandra M Cardona; Cindy E Pouw; Alberto Muniz; Andrew S Mendiola; Andrew T C Tsin; Donald M Allen; Astrid E Cardona
Journal:  J Ophthalmol       Date:  2014-08-31       Impact factor: 1.909

10.  IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways.

Authors:  Xiufen Liu; Fei Ye; Huabao Xiong; Danning Hu; G Astrid Limb; Tian Xie; Liang Peng; Wei Yang; Yabin Sun; Mingming Zhou; E Song; David Y Zhang
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.